Delta-Fly Pharma, Inc.Announces That Dfp-10917, A Leading Pipeline Of The Company, Is Granted Orphan Drug Designation (Odd) By Us Food And Drug Administration (Fda) For The Treatment Of Acute Myeloid Leukemia (Aml).Be Given To Odd, Delta-Fly Pharma, Inc. Can Be Entitled To Seven Extra Years Of Marketing Exclusivity And Receive Some Benefits Such As R&D Rebate By Getting Approval.Dfp-10917 Is An Anti-Cancer Agent In Development For The Treatment Of Patients With Refractory/Relapsed Aml. A Phase 3 Clinical Study Has Been Underway At Md Anderson Cancer Center In Texas And Other Major Sites Of Hematologic Cancer Treatment In Usa. The Company Expects To Complete The Patients
